Neurofibrillary Tangles of Aβ x-40 in Alzheimer’s Disease Brains

Abstract

The two pathognomonic lesions in the brain of AD patients are senile plaques and intraneuronal neurofibrillary tangles (NFT). Previous studies have demonstrated that amyloid-β (Aβ) is a component of both senile plaques and NFTs, and have showed that intracellular accumulation of Aβ is toxic for cells and precedes the appearance of extracellular amyloid deposits. Here we report that there are numerous intraneuronal NFT and extraneuronal NFT immunoreactive for Aβ_x-40 in which there is no co-localization with tau staining suggesting the existence of two different neurodegenerating populations associated with the intracellular accumulation of either tau protein or Aβ_x-40 in AD.

Keywords

Amyloid-β Aβ peptides immunohistochemistry neurodegeneration phosphorylated-tau tau protein

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the progressive and irreversible destruction of neurons in the cerebral cortex. There are two pathognomonic lesions in the brain of AD patients: senile plaques, composed mainly of extracellular aggregates of amyloid-β peptides (Aβ) [1], and intraneuronal neurofibrillary tangles (NFT), consisting of paired helical filaments (PHF) [2] composed primarily of hyperphosphorylated tau protein [3, 4]. The relationship between these processes is uncertain and still not completely understood. The existence of intraneuronal Aβ has been known for many years. Masters and collaborators published in 1985 that Aβ, initially termed amyloid A4, is deposited first intraneuronally as NFT and subsequently in the extracellular space, associated with senile plaques and blood vessels [5]. Later on, the immunolabeling of most intraneuronal NFT (iNFT) and extraneuronal NFT (eNFT) with anti-Aβ antibodies was replicated in several laboratories [6 –8]. However, other studies failed to find Aβ immunolabeling associated with iNFT [9 –11] or with both iNFT and eNFT [12].

Later on, immunostaining with specific antibodies against the C-terminal fragment of either Aβ₄₀ or Aβ₄₂ (Aβ_x-40 or Aβ_x- 42, respectively) enabled the visualization of Aβ₄₂ associated with iNFT where it was seen to collocalize with tau, whereas Aβ₄₀ did not associate at all or to a far lesser degree [13 –15]. Additionally, it was reported that numerous eNFT appeared stained for Aβ_x-40, which was interpreted as a secondary deposition over remnants of iNFT exposed in brain tissue once the cells died; however, evidence of colocalization of Aβ_x-40 with tau protein in these eNFT was lacking [16].

Studies in cell cultures have shown that both Aβ₄₂ and Aβ₄₀ can be intracellularly produced in neurons (but apparently not in other types of cells) [17, 18], mainly in the trans-Golgi network, although production of Aβ₄₂ is observed as well in the endoplasmic reticulum [19]. Numerous studies have shown that the intraneuronal accumulation of Aβ may be toxic and precedes its extracellular deposition both in AD brains and in transgenic mice models of the disease [14 , 20–25]. Interestingly, intraneuronal accumulation of either Aβ₄₀ or Aβ₄₂ has been described in brains of Down syndrome patients aged less than three years [20 , 27]. Furthermore, it has been found that intracellular Aβ deposition precedes the appearance of immunoreactive tau iNFT [20, 28] which subsequently were found associated with Aβ₄₂ in neurites and synapses [15]. These findings led to a modification of the amyloid cascade hypothesis in which the first step of the cascade is the intraneuronal accumulation of Aβ [29].

In this work, we report the finding of numerous Aβ_x-40 positive iNFT and eNFT in the entorhinal, hippocampal and, to a lesser extent, the parietal cortex of AD brains. The Aβ_x-40 staining did not co-localize with tau staining in the same NFTs suggesting that there may be two different neurodegenerating pathways in AD brains leading to the intraneuronal accumulation of either tau or Aβ_x-40.

Paraffin embedded sections from the entorhinal, hippocampus, and parietal cortex of patients (both genders, age range 36-97) diagnosed histopathologically with AD Braak & Braak (B&B; [30]) stages II-III, IV, and VI (N = 3 from each stage), as well as from two Down syndrome (DS) patients with AD (B&B stage VI; N = 2) and from 4 healthy control brains, were immunohistochemically analyzed (for demographic characteristic, see Supplementary Table 1). The tissues were obtained from the Neurological Tissue Bank of the Clinic Hospital at the University of Barcelona in accordance with the Helsinki Declaration of 1975.

Brain sections were deparaffinized incubated for 3 minutes in 90% formic acid for antigen retrieval (except for the AT8 antibody in which a microwave was used) and quenched for endogenous peroxidase with 3.3% hydrogen peroxide and 30% methanol. The antibodies used were: SAR-022 (anti-Aβ_x-40 polyclonal antibody; Araclon Biotech, Zaragoza) at 1 : 500; SAR-031 (anti-Aβ_x- 42 polyclonal antibody; Araclon Biotech, Zaragoza) at 1 : 2000; 6E10 monoclonal antibody (anti-N-terminal region of Aβ; Covance, London) at 1 : 2000; 4G8 monoclonal antibody (anti-central region of Aβ; Covance, London) at 1 : 1000; and AT8 (anti-Phospho-PHF-tau pSer202+Thr205; ThermoFisher Scientific, Waltham) at 1 : 200. The anti Aβ_x-40 and anti Aβ_x- 42 antibodies were purified by antigen-affinity chromatography using the same Aβ fragment inoculated to the rabbits (Aβ_33–40 and Aβ_35–42, respectively). As described elsewhere, they have practically no cross-reactivity (less than 1%) between their target Aβ species nor with Aβ_1–38 (<2%), Aβ_1–43 (<1%) [31].

After overnight incubation with each primary antibody and subsequent washing, the sections were incubated for 45 min in either goat anti-rabbit at 1 : 200 (Sigma, St. Louis) or goat anti-mouse at 1 : 100 (Sigma, St. Louis) for poly- or monoclonal primary antibodies, respectively; followed by 45 min incubation in avidin-biotin (Vectastain ABC kit, Vector lab, Burlingame) and then developed with diaminobencidine as chromogen. Selected sections were double immunofluorescence stained with anti-Aβ_x-40 and AT8 antibodies followed by rodamine-goat anti-rabbit at 1 : 100 (Sigma, St. Louis) or fluorescein-goat anti-mouse at 1 : 100 (Sigma, St. Louis). Specificity of the anti-Aβ_x-40 labeling was assessed by overnight preadsorption of the primary antibody with Aβ_1 -40 peptide (10e-5 M).

The section labeled with the anti-Aβ_x–40 antibody presented (in addition to positively stained diffuse and senile plaques) numerous Aβ_x–40 positive NFTs. These Aβ-NFTs were intensely stained and appeared very similar to the classic tau-NFTs. The Aβ-NFTs were localized in the entorhinal cortex, mainly in the cell islands of layer II, but also in deeper cortical layers (Fig. 1A); in the hippocampus, including dentate gyrus, fields CA1-CA3, and in the subiculum (Fig. 1B) of all the patients analyzed (Braak &Braak stages II-III, IV, and VI) and, to a lesser extent, dispersed within the parietal cortex of the more advanced cases of AD. No Aβ-NFTs were observed in the preparations from the healthy controlbrains.

Fig.1

A-F) Aβ_x-40 immunostaining of AD brain sections (B&B stage VI). A) Clusters of Aβ_x-40 positive NFT are seen in layer II and scattered in deeper layers of entorhinal cortex together with slightly stained senile plaques (arrow heads). B) In the hippocampal formation, Aβ_x-40 positive NFT appeared mainly in the CA1-CA3 fields and in the dentate gyrus. C) Aβ_x-40 positive iNFT in the hippocampus (arrow heads). D) Aβ_x-40 eNFT and iNFT (arrow heads) in the entorhinal cortex. E, F) The sections reacted with 6E10 (E) or 4G8 (F) showing numerous senile plaques but no NFT; asterisks are in the same blood vessel for reference.

Aβ_x-40 positive labeling was seen in the cytoplasm of apparently functional neurons as iNFTs (Fig. 1C, D), but labeling of eNFT was more frequently seen, particularly in advanced AD stages (Fig. 1D). Many of these eNFTs maintained the shape of neurons, although they were normally larger than their unlabeled counterparts, which suggested that these profiles could represent an additional Aβ_x-40 deposition once the parental neurons have lost their plasmatic membrane, leaving the NFTs exposed in the neuropil.

In contrast to the intense labelling obtained with the anti-Aβ_x-40 antibody, we did not see NFT labelling with any of the anti-Aβ monoclonal antibodies that target the N-terminal or central parts of the Aβ peptides, which indicated that Aβ-NFTs were composed of Aβ C-terminal fragments (Fig. 1E, F). Very occasionally we found similar iNFTs and eNFTs marked with the anti-Aβ₄₂ antibody (not shown).

Aβ-NFTs were also found in the brain of a DS patient who had been diagnosed with severe dementia of Alzheimer type. Interestingly, these Aβ_x-40 positive profiles were almost completely lacking in the other non-demented DS patient, in spite of both having been classified as B&B stage VI and both presented extensive Aβ₄₂ burden (Fig. 2A-D).

Fig.2

Contiguous entorhinal sections from two Down syndrome patients, one diagnosed with severe dementia of the Alzheimer type (A-B) and other non-demented (C-D); asterisks are in the same blood vessels for reference. Sections were reacted for Aβ_x-40 (A and C) and Aβ_x- 42 (B and D). Note that whereas both brains presented numerous Aβ_x- 42 positive profiles, Aβ_x-40 positive profiles were almost completely lacking in the non-demented patient. Preadsorption of the first antibody with the immunogenic peptide resulted in a complete absence of the Aβ_x-40 labeling in F with regard to the contiguous positively stained section in E; asterisks are in the same blood vessels for reference. Sections A, E, and F were slightly stained with cresyl violet.

The preadsorption of the anti-Aβ_x-40 antibody with Aβ_1 -40 led to the complete disappearance of staining in both the senile plaques and Aβ-NFTs, demonstrating that the labeling is due to the presence of the Aβ₄₀ C-terminal fragments specifically recognized by our Aβ_x-40 antibody (Fig. 2E, F). Furthermore, double immunofluorescent staining showed that the epitopes for the anti-Aβ₄₀ and AT8 antibodies do not colocalize on the same neurons, whereas they positively colocalize on the diffuse and senile plaques (Fig. 3A-F). These findings allowed us to discard the possibility of that the labelling of Aβ-NFTs was due to a cross-reactivity of our antibody with the tau-NFTs. Thus, two populations of degenerating neurons could be detected and differentiated, one filled with tau and the other with C-terminal fragments of Aβ₄₀.

Fig.3

Double immunofluorescent staining with AT8 anti-tau (green, A and D) and anti-Aβx-40 (red, B and E) antibodies in entorhinal cortex sections. Note that the two labels do not co-localize in the NFT profiles nor in the short threads in A and D (merged in C), whereas both co-localize in the senile plaques (merged in F).

An exaggeratedly antagonistic vision of the two hallmark lesions in AD (extracellular senile plaques mainly containing Aβ and intraneuronal NFTs composed of hyperphosphorylated tau protein) has crystallized into the idea that Aβ triggers neurodegeneration from the outside of cells and a subsequent tau accumulation damages them from inside. This overly simplistic vision disregards pioneers’ results demonstrating that Aβ is a component of both senile plaques and NFTs [5 , 32] and also more recent reports showing that intracellular accumulation of Aβ is toxic for cells and precedes the appearance of extracellular amyloid deposits [14 , 29]. The presence of Aβ_x-40 immunoreactivity in the eNFTs as described in the present work, has been known for a long time [13, 16], yet contradictory results have also been reported [14, 20]. These discrepancies suggest that not all anti-Aβ₄₀ specific antibodies are able to recognize the Aβ₄₀ C-terminal fragments present in the NFT, although they could also be due to differences in the processing of brain sections[8 , 34].

Since the majority of the eNFTs found in those studies were Aβ₄₀ positive, whereas, in contrast, very few iNFTs appeared labelled with anti-Aβ₄₀ antibodies, it was assumed that eNFTs resulted from a secondary deposition of extracellular Aβ₄₀ once the neuron had died and lost its nucleus and its plasmatic membrane. Visualization of tau positive eNFTs was not present in these studies because they were predominantly carried out with the Alz-50 antibody, which targets a tau-epitope known to be lost in the eNFTs [10, 32]. However, in the present work we have used the monoclonal AT8 anti-tau antibody, which has allowed us to label both tau positive iNFT and eNFT, in accordance with previous reports [35]. Interestingly, the Aβ_x-40 staining does not co-localize with the tau staining in the same NFT, while it does co-localize in the diffuse and senile plaques. Thus, two populations of degenerating neurons can be differentiated in a brain with AD, suggesting the existence of at least two different neurodegenerating pathways leading to the intraneuronal accumulation of either tau or Aβ_x-40.

Nevertheless, further experiments analyzing more brains, a larger panel of antibodies targeting not only Aβ₄₀ and phosphorylated tau but also native tau, the ultrastructural characterization of Aβ_x-40 NFTs and their timeline throughout the disease process, will be necessary to test this hypothesis.

In spite of its limitations, the present work comments on the role of Aβ₄₀ in AD which is also underlined by our finding of numerous Aβ_x-40 positive profiles in the brain of a Down syndrome patient with severe dementia while these profiles were almost completely lacking in the brain of a non-demented Down syndrome patient. Although there are controversial reports concerning which Aβ species accumulates intracellularly in DS patients, our result is congruent with previous studies showing an increase of Aβ₄₀ immunoreactive profiles in the brains of Down syndrome patients from 30 years old onwards, when neuropathology rapidly accumulates until it reaches levels sufficient for a diagnosis of AD in most of these patients (for a recent review, see [36]). Currently, it is generally accepted that Aβ₄₂ may be of particular relevance in triggering AD because it is more hydrophobic and prone to aggregate in vitro than Aβ₄₀ [37]. However, it should be considered that the aggregating behavior of the various Aβ species could be different in vivo than in vitro [38] and, in this line, it is also relevant to underline some studies pointing to the relevance of Aβ₄₀ in AD[39, 40].

In conclusion, the present work underlines the possible role for Aβ₄₀ in AD physiopathology as our results have shown the existence of two different neurodegenerating populations alternativelyassociated with the intracellular accumulation of either tau protein or Aβ_x-40.

Footnotes

ACKNOWLEDGMENTS

This work has been financed by Araclon Biotech Ltd.

Authors’ disclosures available online ().

Appendix

References

Glenner

, Wong

, Quaranta

, Eanes

(1984) The amyloid deposits in Alzheimer’s disease: Their nature and pathogenesis. Appl Pathol 2, 357–369.

Mann

(1985) The neuropathology of Alzheimer’s disease: A review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev 31, 213–255.

Kosik

, Joachim

, Selkoe

(1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83, 4044–4048.

Ballatore

, Lee

, Trojanowski

(2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8, 663–672.

Masters

, Multhaup

, Simms

, Pottgiesser

, Martins

, Beyreuther

(1985) Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4, 2757–2763.

Spillantini

, Goedert

, Jakes

, Klug

(1990) Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A 87, 3947–3951.

Spillantini

, Goedert

, Jakes

, Klug

(1990) Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci U S A 87, 3952–3956.

Perry

, Cras

, Siedlak

, Tabaton

, Kawai

(1992) Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 140, 283–290.

Hyman

, Van Hoesen

, Beyreuther

, Masters

(1989) A4 amyloid protein immunoreactivity is present in Alzheimer’s disease neurofibrillary tangles. Neurosci Lett 101, 352–355.

10.

Tabaton

, Cammarata

, Mancardi

, Manetto

, Autilio-Gambetti

, Perry

, Gambetti

(1991) Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad SciU S A 88, 2098–2102.

11.

Yamaguchi

, Nakazato

, Shoji

, Okamoto

, Ihara

, Morimatsu

, Hirai

(1991) Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia. Am J Pathol 138, 699–705.

12.

Ikeda

, Haga

, Oyanagi

, Iritani

, Kosaka

(1992) Ultrastructural and immunohistochemical study of degenerate neurite-bearing ghost tangles. J Neurol 239, 191–194.

13.

Schwab

, McGeer

(2000) Abeta42-carboxy-terminal-like immunoreactivity is associated with intracellular neurofibrillary tangles and pick bodies. Exp Neurol 161, 527–534.

14.

Takahashi

, Milner

, Li

, Nam

, Edgar

, Yamaguchi

, Beal

, Xu

, Greengard

, Gouras

(2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869–1879.

15.

Takahashi

, Capetillo-Zarate

, Lin

, Milner

, Gouras

(2010) Co-occurrence of Alzheimer’s disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging 31, 1145–1152.

16.

Schwab

, Akiyama

, McGeer

(1998) Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of beta-amyloid protein. J Neuropathol Exp Neurol 57, 1131–1137.

17.

Wertkin

, Turner

, Pleasure

, Golde

, Younkin

, Trojanowski

, Lee

(1993) Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. Proc Natl Acad Sci U S A 90, 9513–9517.

18.

Hartmann

, Bieger

, Bruhl

, Tienari

, Ida

, Allsop

, Roberts

, Masters

, Dotti

, Unsicker

, Beyreuther

(1997) Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med 3, 1016–1020.

19.

Greenfield

, Tsai

, Gouras

, Hai

, Thinakaran

, Checler

, Sisodia

, Greengard

, Xu

(1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A 96, 742–747.

20.

Gouras

, Tsai

, Naslund

, Vincent

, Edgar

, Checler

, Greenfield

, Haroutunian

, Buxbaum

, Xu

, Greengard

, Relkin

(2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15–20.

21.

Wirths

, Multhaup

, Czech

, Blanchard

, Moussaoui

, Tremp

, Pradier

, Beyreuther

, Bayer

(2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306, 116–120.

22.

Oddo

, Caccamo

, Shepherd

, Murphy

, Golde

, Kayed

, Metherate

, Mattson

, Akbari

, LaFerla

(2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421.

23.

Oddo

, Caccamo

, Smith

, Green

, LaFerla

(2006) A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 168, 184–194.

24.

Knobloch

, Konietzko

, Krebs

, Nitsch

(2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28, 1297–1306.

25.

Umeda

, Ramser

, Yamashita

, Nakajima

, Mori

, Silverman

, Tomiyama

(2015) Intracellular amyloid beta oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathol Commun 3, 51.

26.

Gyure

, Durham

, Stewart

, Smialek

, Troncoso

(2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125, 489–492.

27.

Mori

, Spooner

, Wisniewsk

, Wisniewski

, Yamaguchi

, Saido

, Tolan

, Selkoe

, Lemere

(2002) Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9, 88–102.

28.

Fernandez-Vizarra

, Fernandez

, Castro-Blanco

, Serrano

, Bentura

, Martinez-Murillo

, Martinez

, Rodrigo

(2004) Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer’s disease. Histol Histopathol 19, 823–844.

29.

Wirths

, Multhaup

, Bayer

(2004) A modified beta-amyloid hypothesis: Intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. J Neurochem 91, 513–520.

30.

Braak

, Braak

(1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239–259.

31.

Perez-Grijalba

, Fandos

, Canudas

, Insua

, Casabona

, Lacosta

, Montanes

, Pesini

, Sarasa

(2016) Validation of immunoassay-based tools for the comprehensive quantification of Abeta40 and Abeta42 peptides in plasma. J Alzheimers Dis 54, 751–762.

32.

Perry

, Richey

, Siedlak

, Smith

, Mulvihill

, DeWitt

, Barnett

, Greenberg

, Kalaria

(1993) Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 143, 1586–1593.

33.

D’Andrea

, Nagele

, Wang

, Lee

(2002) Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer’s disease entorhinal cortex. Neurosci Lett 333, 163–166.

34.

D’Andrea

, Reiser

, Polkovitch

, Gumula

, Branchide

, Hertzog

, Schmidheiser

, Belkowski

, Gastard

, Andrade-Gordon

(2003) The use of formic acid to embellish amyloid plaque detection in Alzheimer’s disease tissues misguides key observations. Neurosci Lett 342, 114–118.

35.

Augustinack

, Schneider

, Mandelkow

, Hyman

(2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103, 26–35.

36.

Head

, Lott

, Wilcock

, Lemere

(2016) Aging in Down syndrome and the development of Alzheimer’s disease neuropathology. Curr Alzheimer Res 13, 18–29.

37.

Selkoe

(2001) Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev 81, 741–766.

38.

Shin

, Ogino

, Kondo

, Saido

, Trojanowski

, Kitamoto

, Tateishi

(1997) Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J Neurosci 17, 8187–8193.

39.

Naslund

, Schierhorn

, Hellman

, Lannfelt

, Roses

, Tjernberg

, Silberring

, Gandy

, Winblad

, Greengard

, Nordstedt

, Terenius

(1994) Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91, 8378–8382.

40.

Wang

, Dickson

, Trojanowski

, Lee

(1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 158, 328–337.